Viatris Can't Keep Novo's Weight Loss Drug IP Suit In W.Va.
The U.S. Judicial Panel on Multidistrict Litigation has rejected Viatris' calls to have Novo Nordisk's drug patent suit against it over diabetes drug Ozempic stay in West Virginia federal court, centralizing...To view the full article, register now.
Already a subscriber? Click here to view full article